Pathos AI has signed a collaboration and co-exclusive licensing agreement with Astrazeneca plc to advance AZD-4241, a preclinical investigational therapy for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.